pargyline has been researched along with Parkinson Disease, Secondary in 12 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (75.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Langston, JW | 2 |
| Irwin, I | 2 |
| Langston, EB | 2 |
| Forno, LS | 1 |
| Cohen, G | 1 |
| Pasik, P | 1 |
| Cohen, B | 1 |
| Leist, A | 1 |
| Mytilineou, C | 1 |
| Yahr, MD | 1 |
| Eberling, JL | 1 |
| Bankiewicz, KS | 1 |
| Jordan, S | 1 |
| VanBrocklin, HF | 1 |
| Jagust, WJ | 1 |
| Kohutnicka, M | 1 |
| Lewandowska, E | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Członkowski, A | 1 |
| Członkowska, A | 1 |
| Andringa, G | 1 |
| van Oosten, RV | 1 |
| Unger, W | 1 |
| Hafmans, TG | 1 |
| Veening, J | 1 |
| Stoof, JC | 1 |
| Cools, AR | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Youdim, MB | 1 |
| Finberg, JP | 1 |
| Barbeau, A | 2 |
| Dallaire, L | 2 |
| Buu, NT | 2 |
| Veilleux, F | 1 |
| Boyer, H | 1 |
| de Lanney, LE | 1 |
| Poirier, J | 1 |
| Rucinska, E | 1 |
| Snyder, AM | 1 |
| Stricker, EM | 1 |
| Zigmond, MJ | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
1 review available for pargyline and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
11 other studies available for pargyline and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Pargyline prevents MPTP-induced parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Male; Neurons; Pargyline; Pa | 1984 |
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Dopamine; Female; Homovanill | 1984 |
PET studies of functional compensation in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Progression; Dopamin | 1997 |
Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Disease Models, Animal; Dopamine; | 1998 |
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
Topics: Animals; Antibodies; Apoptosis; Behavior, Animal; Body Weight; Denervation; Dopamine; Exploratory Be | 2000 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain Chemistry; | 1985 |
Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adrenal Medulla; Animals; | 1985 |
Stress-induced neurological impairments in an animal model of parkinsonism.
Topics: Animals; Bupropion; Corpus Striatum; Deoxyglucose; Desipramine; Dopamine; Dose-Response Relationship | 1985 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |